Activated ras Prevents Downregulation of Bcl-XL Triggered by Detachment from the Extracellular Matrix: A Mechanism of ras-Induced Resistance to Anoikis in Intestinal Epithelial Cells by Rosen, Kirill et al.
 
ã
 
 The Rockefeller University Press, 0021-9525/2000/04/447/9 $5.00
The Journal of Cell Biology, Volume 149, Number 2, April 17, 2000 447–455
http://www.jcb.org 447
 
Activated 
 
ras
 
 Prevents Downregulation of Bcl-X
 
L
 
 Triggered by Detachment 
from the Extracellular Matrix: A Mechanism of 
 
ras
 
-induced Resistance to 
Anoikis in Intestinal Epithelial Cells
 
Kirill Rosen,*
 
‡
 
 Janusz Rak,*
 
‡
 
 Thomas Leung,*
 
‡
 
 Nicholas M. Dean,
 
§
 
 Robert S. Kerbel,*
 
‡
 
 and Jorge Filmus*
 
‡
 
*Division of Cancer Biology Research, Sunnybrook and Women’s College Health Science Centre, 
 
‡
 
Department of Medical 
Biophysics, University of Toronto, Ontario, Canada M4N 3M5; 
 
§
 
Isis Pharmaceuticals, Carlsbad, California 92008
 
Abstract. 
 
Detachment of epithelial cells from the ex-
tracellular matrix (ECM) results in a form of apoptosis 
often referred to as anoikis. Transformation of intesti-
 
nal epithelial cells by oncogenic 
 
ras
 
 leads to resistance 
to anoikis, and this resistance is required for the full 
manifestation of the malignant phenotype. Previously, 
we demonstrated that 
 
ras
 
-induced inhibition of anoikis 
in intestinal epithelial cells results, in part, from the 
 
ras
 
-
 
induced constitutive downregulation of Bak, a pro-apop-
totic member of the Bcl-2 family. Since exogenous Bak 
could only partially restore susceptibility to anoikis in 
the 
 
ras
 
-transformed cells, the existence of at least an-
other component of the apoptotic machinery mediating 
the effect of activated 
 
ras
 
 on anoikis was suggested. In-
deed, here we show that, in nonmalignant rat and hu-
man intestinal epithelial cells, detachment from the 
ECM or disruption of the cytoskeleton results in a sig-
niﬁcant downregulation of the antiapoptotic effector 
 
Bcl-X
 
L
 
, and that activated H- or K-
 
ras 
 
oncogenes com-
pletely abrogate this downregulation. In addition, we 
found that enforced downregulation of Bcl-X
 
L
 
 in the 
 
ras
 
-transformed cells promotes anoikis and signiﬁcantly 
inhibits tumorigenicity, indicating that disruption of the 
adhesion-dependent regulation of Bcl-X
 
L
 
 is an essential 
part of the molecular changes associated with transfor-
mation by 
 
ras
 
. While the 
 
ras
 
-induced downregulation of 
Bak could be reversed by pharmacological inhibition of 
phosphatidylinositol 3 kinase (PI 3-kinase), the effect 
 
of 
 
ras 
 
on Bcl-X
 
L
 
 was PI 3-kinase– and mitogen-activated 
protein kinase (MAP kinase)–independent. We con-
clude that 
 
ras
 
-induced resistance to anoikis in intestinal 
epithelial cells is mediated by at least two distinct 
mechanisms: one that triggers downregulation of Bak 
and another that stabilizes Bcl-X
 
L
 
 expression in the 
absence of the ECM.
Key words: apoptosis • colorectal tumors • cytoskele-
ton • PI 3-kinase • MAP kinase
 
Introduction
 
Survival of normal epithelial cells is dependent on signals
generated by the interaction of these cells with compo-
nents of their basement membrane (Ruoslahti and Reed,
1994; Frisch and Ruoslahti, 1997). The absence of such sig-
nals triggers a form of physiological cell death, which re-
cently has been named anoikis or death of homelessness,
as it is believed to affect cells outside of their proper tissue
context (Frisch and Francis, 1994; Meredith and Schwartz,
1997). Anoikis is thought to play an important role in
maintaining proper tissue architecture by precluding reat-
tachment and growth of epithelial cells at ectopic locations
(Frisch and Ruoslahti, 1997).
Several lines of evidence indicate that the acquisition of
resistance to anoikis plays a central role in the progression
of human carcinomas. First, solid tumors grow in vivo as
multicellular masses in which the cells are forced to survive
in the absence of attachment to a properly formed base-
ment membrane. Second, most cell lines derived from such
solid tumors are capable of growing in an anchorage-inde-
pendent manner as colonies in soft agar or suspension cul-
ture (Schwartz, 1997). Third, nonmalignant epithelial cells,
which were selected for the ability to resist anoikis in tissue
culture, simultaneously acquire a tumor-forming capacity
(Rak et al., 1999). Fourth, suppression of the resistance to
anoikis in cultured transformed epithelial cells strongly in-
hibits their tumorigenicity (Rosen et al., 1998). Fifth, trans-
fection of nonmalignant epithelial cells with various onco-
genes commonly associated with epithelial malignancies,
such as mutant H- or K-
 
ras
 
,
 
 
 
induces resistance to anoikis
(Frisch and Francis, 1994; Rak et al., 1995).
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Activating mutations of the 
 
ras
 
 proto-oncogene are
among the most frequent oncogenic events in human can-
cer (Barbacid, 1987; Bos et al., 1987; Forrester et al., 1987;
Almoguera et al., 1988). Ras is a small GTPase that acts as
a molecular switch by regulating the passage of signals
from growth factor receptors and other extracellular
queues to signaling pathways that control expression of
various effector genes (McCormick, 1993; Marshall, 1996).
In this manner, 
 
ras
 
 exerts a regulatory effect on diverse
cellular functions such as proliferation (Filmus et al., 1994),
cytoskeletal organization (Hall, 1990; Rodriguez-Viciana
et al., 1997), and survival (Downward, 1998). Oncogenic
 
ras
 
, which is locked in a constitutively active (GTP-bound)
state, alters these cellular functions, and contributes in this
way to the malignant transformation of various cell types
including those from the intestinal epithelium (Bos et al.,
1987; Forrester et al., 1987). One of the consequences of
the disruptive effect of activated 
 
ras
 
 on normal cell physi-
ology is the induction of resistance to anoikis (Frisch and
Francis, 1994). We have recently demonstrated that this
loss of susceptibility to anoikis is a critical component of
the tumorigenic phenotype of 
 
ras
 
-transformed intestinal
epithelial cells (Rosen et al., 1998).
The molecular mechanisms governing the switch to the
anoikis-resistant state associated with 
 
ras-
 
induced trans-
formation have just started to be uncovered. It is generally
believed that programmed cell death can be triggered by a
specific set of signals, which lead to the release of cyto-
chrome 
 
c 
 
from the mitochondria into the cytoplasm (Nunez
et al., 1998). Cytochrome 
 
c
 
 interacts with the regulatory
protein Apaf-1, inducing the activation of caspases, which
are serine proteases that cleave a set of critical cellular tar-
gets. At this point, the cell death program enters its irre-
versible stage (Green and Reed, 1998). The release of cy-
tochrome 
 
c
 
 from the mitochondria is both positively and
negatively regulated by members of the Bcl-2 protein fam-
ily (Adams and Cory, 1998; Chao and Korsmeyer, 1998;
Kelekar and Thompson, 1998; Reed, 1998). Bcl-2, Bcl-X
 
L
 
,
and Bcl-w are some of the antiapoptotic members of this
family, whereas Bak, Bax, and Bad are examples of the
pro-apoptotic group (Adams and Cory, 1998). Caspase ac-
tivity can also be directly inhibited by members of a sepa-
rate gene family known as inhibitors of apoptosis (IAPs)
 
1
 
(LaCasse et al., 1998). In addition, the caspase cascade can
be triggered by a specialized cell death pathway after en-
gagement of members of the tumor necrosis factor recep-
tor family (Nunez et al., 1998).
As a result of our initial attempt to investigate the effect
of the 
 
ras
 
 oncogene on the apoptotic machinery of a non-
malignant intestinal epithelial cell line (IEC-18), we have
reported that activated 
 
ras
 
 induces constitutive downregu-
lation of Bak (Rosen et al., 1998). Interestingly, downreg-
ulation of Bak has been found in a large proportion of hu-
man colorectal carcinomas, indicating that our finding has
clinical implications (Krajewska et al., 1996). At the func-
tional level, we have shown that ectopic expression of Bak
in 
 
ras
 
-transformed rat intestinal epithelial cells markedly
diminishes 
 
ras
 
-induced resistance to anoikis, and signifi-
 
cantly reduces tumorigenicity of these cells in nude mice.
Overall, our results indicated that the ability of activated
 
ras
 
 to downregulate Bak, and the consequent resistance to
anoikis, is essential for the malignant transformation of in-
testinal epithelial cells induced by this oncogene. At the
mechanistic level, we noted that the impact of activated
 
ras
 
 on Bak expression could be partially prevented by
pharmacological inhibition of phosphatidylinositol 3 kinase
(PI 3-kinase), an immediate downstream target of 
 
ras
 
(Rodriguez-Viciana et al., 1994). This observation is con-
sistent with a previous report implicating this enzyme in
the induction of resistance to anoikis in a 
 
ras
 
-transformed
epithelial cell line derived from the kidney (Khwaja et al.,
1997). These data are also compatible with a general per-
ception that PI 3-kinase is a mediator of cell survival sig-
nals under a variety of circumstances acting through the
activation of protein kinase B (PKB; Franke et al., 1997;
Marte and Downward, 1997). Our study also suggested
that effectors other than Bak must be involved in 
 
ras
 
-
induced resistance to anoikis. This conclusion was based
on the fact that expression of exogenous Bak in the 
 
ras
 
-
transformed cells at levels similar to or even higher than
those of the parental IEC-18 cells caused only partial res-
toration of the susceptibility to anoikis. Therefore, we de-
cided to investigate whether other components of the
apoptotic machinery act as effectors of the
 
 ras
 
-induced re-
sistance to anoikis in intestinal epithelial cells.
Bcl-X
 
L
 
, an antiapoptotic member of the Bcl-2 family, is
upregulated in 
 
z
 
50% of cancers derived from intestinal
epithelium (Krajewska et al., 1996). Here, we report that
Bcl-X
 
L
 
 is an important mediator of the effect of 
 
ras
 
 on
anoikis in intestinal epithelial cells. Our results show that
detachment of such nonmalignant cells from the ECM re-
sults in a strong downregulation of Bcl-X
 
L
 
 expression, and
that this downregulation is blocked by transformation with
activated H- and K-
 
ras
 
 oncogenes. In addition, we show
that ectopic expression of Bcl-X
 
L
 
 in nontransformed intes-
tinal epithelial cells strongly inhibits anoikis, whereas en-
forced downregulation of Bcl-X
 
L 
 
in the 
 
ras
 
-transformed
cells has an opposite effect with a parallel decrease in tu-
morigenicity of such cells.
 
Materials and Methods
 
Cell Culture
 
The IEC-18 cells were obtained from Dr. A. Quaroni (Cornell University,
Ithaca, NY). The generation of the IEC clones expressing activated H-
 
ras
 
constitutively or under the control of the inducible metallothionein pro-
moter (MT-
 
ras
 
) has been previously described (Filmus et al., 1992, 1993).
All IEC clones were cultured in 
 
a
 
-MEM containing 5% FBS, 10 
 
m
 
g/ml in-
sulin, and 0.5% glucose. H-
 
ras
 
 expression in the MT-
 
ras
 
 clone was in-
duced by adding 100 
 
m
 
M ZnCl
 
2
 
 and 2 
 
m
 
M CdCl
 
2
 
 to cells 48 h before the
experiment. The DLD-1, DKO-3, and DKS-8 colorectal tumor cell lines
were provided by T. Sasazuki (Kyushu University, Fukuoka, Japan;
Shirasawa et al., 1993). These cells were cultured in DME containing 10%
FBS. The generation of the IEC-18 variant, which is resistant to anoikis
(AR 1.10), has been described elsewhere (Rak et al., 1995). For suspen-
sion cultures, 10
 
6
 
 cells were plated above a layer of 1% sea plaque agarose
polymerized in 
 
a
 
-MEM or DME.
 
Vector Construction and Transfection
 
To generate the sense and antisense Bcl-X
 
L
 
 expression vectors, the human
Bcl-X
 
L
 
 cDNA was inserted into the EcoRI site of pcDNA3 (Invitrogen
Corp.) in the sense and antisense orientations. To generate IEC-18 cells
 
1
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stably expressing exogenous Bcl-X
 
L
 
, 10
 
6
 
 IEC-18 cells were transfected
with 10 
 
m
 
g of the sense Bcl-X
 
L
 
 expression vector by using lipofectin.
Transfected cells were selected in 400 
 
m
 
g/ml of G418. Selected clones were
expanded, and Bcl-X
 
L
 
 expression was assessed by Western blotting. To
generate IEC-
 
ras
 
 cells stably expressing antisense Bcl-X
 
L
 
, 2.5 
 
3 
 
10
 
5
 
 IEC-
 
ras
 
-3 cells were cotransfected by using lipofectin with 10 
 
m
 
g of the expres-
sion vector, carrying the human Bcl-X
 
L
 
 cDNA in an antisense orientation,
and 1 
 
m
 
g of pZeoSV vector carrying a zeocin resistance gene. Transfected
cells were selected in 250 
 
m
 
g/ml of zeocin. Surviving clones were ex-
panded, and Bcl-X
 
L
 
 expression was assessed by Western blotting.
 
Transfection with Antisense Oligonucleotides
 
5 
 
3 
 
10
 
4
 
 IEC-
 
ras
 
-3 cells were plated on a 60-mm dish. The next day, cells
were incubated with the oligonucleotides (300 nM) in the presence of 7.5
 
m
 
g/ml of lipofectin in 1 ml of OPTI MEM for 4 h. The transfection mix-
ture was replaced by 
 
a
 
-MEM with standard ingredients (see above). Cells
were grown overnight and processed for Western blotting or assayed
for anoikis as described below. Oligonucleotides were obtained from
ISIS Pharmaceuticals (Taylor et al., 1999). The sequence of the antisense
Bcl-X
 
L
 
 oligonucleotide (ISIS 16009) was CTACGCTTTCCACGCACAGT,
and the sequence of the control-scrambled oligonucleotide (ISIS 20574)
was CTCCGATGTCCCCTCAAAGT. All internucleotide bonds were
phosphorothioated. Underlined residues indicate 2
 
9
 
-O-methoxyethyl modi-
fication.
 
Western Blot Analysis
 
Cells were lysed for 30 min on ice in a buffer containing 50 mM Tris-HCl,
pH 8.0, 120 mM NaCl, 100 mM NaF, 0.5% NP-40, 1 mM PMSF, 50 
 
m
 
g/ml
aprotinin, and 10 
 
m
 
g/ml leupeptin. After removing the insoluble material,
aliquots of supernatant containing 20–30 
 
m
 
g of protein were run through a
10% polyacrylamide gel under reducing conditions. Proteins were trans-
ferred to a nylon membrane that was subsequently incubated for 1 h at
room temperature in TBST buffer (125 mM Tris-HCl, pH 8.0, 625 mM
NaCl, and 0.5% Tween 20) containing 4% skim milk. The membrane was
incubated with one of the following antibodies: anti-Bcl-X
 
L
 
, anti-Bad
(Transduction Laboratories) or, in case of the IEC-18–derived clones
transfected with human Bcl-X
 
L
 
 and in the experiments with cell lines de-
rived from human colorectal carcinomas, anti-Bcl-X
 
S/L
 
 (Santa Cruz Bio-
technology), anti-rat Akt (UBI), anti–phospho-Akt (Ser 473), anti–phos-
pho-MAPK, anti-MAPK (New England Biolabs), or anti-Bax, anti-CDK4
(Santa Cruz Biotechnology). Incubation with antibodies was performed in
a TBST buffer containing 5% BSA for 1–2 h. Binding of the antibodies was
detected with the enhanced chemiluminescence system (New England
Nuclear).
 
Northern Blot Analysis
 
Northern blot analysis was performed on total RNA. A human Bcl-X
 
L
 
cDNA labeled with [
 
32
 
P]dCTP by random priming was used as a probe.
 
Apoptosis Assay
 
5 
 
3 
 
10
 
4
 
 cells were plated on a 60-mm or a 100-mm dish in a monolayer or
in suspension. At the indicated time points, cells were removed from the
plates, washed once with PBS, and assayed for the presence of nucleoso-
mal fragments in the cytoplasm by a cell death detection ELISA kit (Boeh-
ringer Mannheim) according to the manufacturer’s instructions.
 
Soft Agar Colony Formation Assay
 
5,000 cells were suspended in 2 ml of IEC medium containing 0.3% of
melted bacto-agar. The resulting suspension was added to a 60-mm plate
covered with a 2-ml layer of solidified 0.5% bacto-agar in 
 
a
 
-MEM. Cell
colonies (
 
.
 
50 cells) were allowed to form for 7–10 d and counted. Each
experiment was performed in triplicate.
 
Tumorigenicity Assay
 
1.6 
 
3 
 
10
 
5
 
 cells were suspended in 0.2 ml of PBS and injected subcutane-
ously into an 8–12-wk-old female nude athymic BALB/C mice. The tu-
mors were measured at the indicated time points by using a Vernier’s cal-
liper, and tumor volume was calculated by using the standard formula:
 
(1)
where 
 
a
 
 is width and 
 
b
 
 is length of the ellipsoid tumor perimeter.
 
Results
 
Activated ras Inhibits Downregulation of Bcl-X
 
L
 
 
Triggered by Detachment from the ECM
 
The search for effectors that mediate the 
 
ras
 
-induced re-
sistance to anoikis led us to compare the levels of Bcl-X
 
L
 
in the nonmalignant rat intestinal epithelial cell line IEC-18
and in the previously characterized IEC-
 
ras
 
–transformed
clone IEC-ras-3 (Filmus et al., 1992) that was cultured in a
monolayer and in suspension. Detachment of IEC-18 cells
from the ECM resulted in a strong downregulation of
Bcl-XL expression. On the other hand, this downregula-
tion was completely abrogated in case of the ras-trans-
formed clone (Fig. 1 A). Similar changes were observed at
the mRNA level (Fig. 1 B). The ras-induced stabilization
of Bcl-XL levels in the absence of ECM was also observed
in two other previously characterized IEC-18–derived
clones constitutively expressing the activated H-ras onco-
gene (ras-4 and ras-7; Fig. 1 C; Filmus et al., 1992, 1994).
To confirm that this stabilization of Bcl-XL expression in
detached cells is a direct consequence of the action of on-
cogenic ras, we used an IEC-18–derived clone (MT-ras) in
which exogenous activated H-ras is expressed under the
control of a metallothionein promoter, which is inducible
by Zn21 and Cd21 (Filmus et al., 1994). Similar to what was
observed in clones expressing activated ras constitutively,
the induction of activated H-ras expression in the MT-ras
cells significantly inhibited downregulation of Bcl-XL
upon cell detachment (Fig. 1 D).
To validate this observation in a different cellular sys-
tem, we employed the highly tumorigenic human colorec-
tal cancer cell line DLD-1, which was harboring a single
copy of the activated K-ras oncogene, and its two variants
DKS-8 and DKO-3 in which the mutant ras allele has been
disrupted by homologous recombination (Shirasawa et al.,
1993). It already has been reported that the ablation of
activated ras from DLD-1 cells strongly inhibits their
anchorage-independent growth and tumorigenicity (Shira-
sawa et al., 1993). Fig. 2 A shows that the removal of the
oncogene from DLD-1 cells also induces sensitivity to
anoikis, since when DKS-8 and DKO-3 cells were placed
in suspension, they displayed significantly higher levels of
death compared with the K-ras–expressing DLD-1 cells.
In agreement with what was found in IEC cells, deletion of
activated K-ras from the DLD-1 cells restored the adhe-
sion-dependent regulation of Bcl-XL expression in DKS-8
and DKO-3 cells (Fig. 2 B).
Transduction of many signals generated by cell–ECM
interactions requires the maintenance of an intact actin cy-
toskeleton (Clark and Brugge, 1995). Therefore, we decided
to verify whether treatment with drugs that disrupt actin
assembly, such as cytochalasin D (CD), has the same ef-
fect on Bcl-XL expression as culturing cells in suspension.
As shown on Fig. 3 A, incubation of IEC-18 and IEC-ras-3
cells with CD strongly inhibited spreading of these cells on
the tissue culture dish. Similar to what was observed after
detachment from the ECM, CD treatment induced a sig-
a
2 b ´
2
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nificant downregulation of Bcl-XL in IEC-18 cells, but did
not affect the expression of this antiapoptotic molecule in
the ras-transformed clones (Fig. 3 B). As might be ex-
pected, treatment with CD had a severe impact on the sur-
vival of the parental IEC-18 cells, whereas in case of the
ras-transfectants CD-induced apoptosis was strongly in-
hibited (Fig. 3 C). These results are consistent with those
obtained with the cells cultured in suspension, and indicate
that the integrity of the actin cytoskeleton represents an
important requirement for the maintenance of the consti-
tutive Bcl-XL expression and survival in case of IEC-18 but
not IEC-ras cells.
Downregulation of Bcl-XL in Response to Cell 
Detachment Contributes to Anoikis
To verify whether the downregulation of Bcl-XL expres-
sion in detached cells plays a role in anoikis, it was impor-
tant to establish that such downregulation occurs before
the detachment-induced cell death. As shown in Fig. 4 A,
Bcl-XL expression was inhibited as early as 0.5 h after plac-
ing the IEC-18 cells in suspension, whereas no significant
apoptosis was observed even after 1 h of suspension cul-
ture (Fig. 4 B), suggesting that the loss of Bcl-XL plays a
causal role in this process. To confirm this more defini-
tively, we transfected IEC-18 cells with a vector in which
Bcl-XL expression was driven by a heterologous promoter.
Four independent clones (Bcl-X 3, 11, 27, and 41) express-
ing exogenous Bcl-XL at levels significantly higher than in
the IEC-18 cells (Fig. 5 A) were generated and tested for
survival in the suspension culture. In all of the Bcl-XL–
transfected clones, a strong protection from apoptosis was
consistently observed (Fig. 5 B). It is important to note
that, although three of the Bcl-XL–transfected clones dis-
played significantly higher levels of Bcl-XL than the IEC-
ras-3 cells when placed in suspension, the protection from
apoptosis in clone 41, which expressed Bcl-XL at levels
similar to those in the IEC-ras-3 cells, was considerable.
Interestingly, expression of Bcl-XL in IEC-18 cells at levels
even higher than in the IEC-ras-3 clone did not provide
the degree of protection against anoikis that was observed
in the case of ras-transformed cells. These data suggest
that ras may inhibit anoikis through both Bcl-XL–depen-
Figure 1. Expression of acti-
vated H-ras in intestinal epithe-
lial cells prevents downregula-
tion of Bcl-XL, which is caused
by cell detachment. (A) West-
ern blot analysis of Bcl-XL in
IEC-18 cells and an H-ras–
transformed clone IEC-ras-3
that were cultured in mono-
layer (mon) or in suspension
(susp) overnight. (B) Northern
blot analysis of Bcl-XL in IEC-
18 cells and clone ras-3 that
were cultured in monolayer
(mon) or in suspension (susp)
overnight. (C) Western blot
analysis of Bcl-XL in IEC-18
cells  and three indepen-
dently derived H-ras–trans-
formed  clones (ras-3, ras-4,
and ras-7) cultured in mono-
layer (mon) or in suspension
(susp) overnight. (D) Western blot analysis of Bcl-XL in MT-ras and IEC-18 cells that were cultured in monolayer (mon) or in suspension (susp)
for 4.5 h in the absence (2) and in the presence (1) of Zn21 and Cd 21. CDK 4 in A, C, and D, and ribosomal RNAs in B were used as loading controls.
Figure 2. Targeted disruption of the activated K-ras allele in cells
derived from human colorectal carcinoma restores sensitivity to
anoikis, and adhesion-dependent regulation of Bcl-XL expres-
sion. (A) Analysis of apoptosis by cell death ELISA in DLD-1,
DKS-8, and DKO-3 cells that were cultured in suspension over-
night. Results represent the average of two independent experi-
ments plus the SD. (B) Western blot analysis of Bcl-XL was per-
formed in cells that were cultured in monolayer (mon) or in
suspension (susp) for the indicated time periods. Membranes
were reprobed with an anti-CDK 4 antibody as a loading control.Rosen et al. Stabilization of Bcl-XL Expression Mediates ras-induced Inhibition of Anoikis451
dent and –independent mechanisms, which is consistent
with our previous finding indicating that a part of the ef-
fect of ras is exerted through a constitutive downregula-
tion of Bak (Rosen et al., 1998).
Further evidence that is consistent with a causal role of
Bcl-XL in the inhibition of anoikis came from the analysis
of an anoikis-resistant (AR) IEC-18 variant which was ob-
tained by serial passage of these cells in intermittent sus-
pension culture, as we described earlier (Rak et al., 1995).
This variant is significantly anoikis resistant (Fig. 6 A),
and, unlike the parental IEC-18 cells, is tumorigenic in
nude mice (Rak et al., 1999). Interestingly, Bcl-XL levels in
these cells were not reduced by lack of attachment. On the
contrary, the expression of Bcl-XL was dramatically in-
creased upon placing the AR variant in the suspension cul-
ture (Fig. 6 B).
ras-induced Stabilization of Bcl-XL Expression 
Contributes to the Anoikis Resistance and 
Tumorigenicity of ras-transformed Cells
To assess the role of Bcl-XL in ras-induced resistance to
anoikis, IEC-ras-3 cells were transiently transfected with
an antisense Bcl-XL oligodeoxyribonucleotide, which was
previously demonstrated to induce downregulation of Bcl-
XL expression in a specific manner (Taylor et al., 1999). As
shown in Fig. 7 A, such transfection resulted in a significant
downregulation of Bcl-XL compared with the mock-trans-
fected cells or cells transfected with a control (scrambled)
oligonucleotide. Transfected cells were cultured in mono-
layer or in suspension and apoptosis was measured. We ob-
served that transfection of IEC-ras-3 cells with the anti-
sense oligonucleotide resulted in a noticeable increase of
anoikis of these cells compared with the controls (Fig. 7 B).
To be able to study the effect of Bcl-XL downregulation
in long-term assays, IEC-ras-3 cells were transfected with
an antisense Bcl-XL expression vector to generate perma-
nent cell lines. Two clones (designated as Bcl-X 65 and 66)
Figure 3.  Activated ras inhibits downregulation of Bcl-XL and
apoptosis in IEC-18 cells treated with cytochalasin D (CD). (A)
Microphotographs of IEC-18 and IEC-ras-3 cells that were
grown in monolayer with and without treatment with 10 mg/ml of
CD for 16 h. (B) Western blot analysis of Bcl-XL in IEC-18 and
IEC-ras-3 cells that were grown in monolayer with (1) and with-
out (2) treatment with CD for 16 h. Membranes were reprobed
with anti-CDK 4 antibody as a loading control. (C) Analysis of
apoptosis by cell death ELISA in IEC-18 and IEC-ras-3 cells
grown in monolayer with (1) and without (2) treatment with 10
mg/ml of CD for 16 h. A similar volume of DMSO (vehicle) was
added to the untreated cells. Results represent the average of
three independent experiments plus the SEM.
Figure 4. Inhibition of Bcl-XL expression caused by cell detach-
ment precedes the onset of anoikis. (A) Western blot analysis of
Bcl-XL in IEC-18 cells that were cultured in monolayer (mon) or
in suspension (susp) for the indicated time periods. The mem-
brane was reprobed with anti-CDK 4 antibody as a loading con-
trol. (B) Analysis of apoptosis by cell death ELISA in IEC-18
cells that were cultured in monolayer (mon) or in suspension
(susp) for the indicated time periods. Results represent the aver-
age of two independent experiments plus the SD.The Journal of Cell Biology, Volume 149, 2000 452
were found to express significantly less Bcl-XL than the
parental IEC-ras-3 cells or a clone transfected with vector
alone (designated vector 75; Fig. 8 A). When cultured in
suspension, the antisense Bcl-X clones displayed levels of
Bcl-XL comparable to those in IEC-18 cells (Fig. 8 B). The
levels of other Bcl-2 family members such as Bak, Bax,
and Bad were not changed in response to the antisense
vector (Fig. 8 A), and no obvious differences in morphol-
ogy and growth rates in monolayer culture were observed
between any of these cell lines. Unlike the controls, cells
expressing antisense Bcl-XL displayed a significant in-
crease in anoikis (Fig. 8 C). Consistent with these data, the
ability of the antisense Bcl-XL clones to grow in soft agar
was strongly inhibited (Fig. 8 D). Furthermore, in good
agreement with the tissue culture studies, cells expressing
low levels of Bcl-XL were markedly less tumorigenic in vivo
than the respective controls (Fig. 8 E). Taken together,
these results indicate that the ras-induced stabilization of
Bcl-XL levels under anchorage-independent conditions is
required for full manifestation of anoikis resistance and
the tumorigenic phenotype caused by this oncogene. How-
ever, it is important to note that although the effects of
Bcl-XL downregulation on anoikis and tumor growth were
significant, they were incomplete. This was expected since,
as discussed previously, part of the effect of activated ras
Figure 5. Anoikis of IEC-18 cells can be inhibited by expression
of exogenous Bcl-XL. (A) Western blot analysis of Bcl-XL in the
following clones placed in suspension: IEC-ras-3, parental IEC-
18 cells, and IEC-18 clones transfected with a Bcl-XL expression
vector (Bcl-X 3, 11, 27, and 41), or vector alone (vector 22). The
membrane was reprobed with anti-CDK 4 antibody as a loading
control. (B) Analysis of apoptosis by cell death ELISA in IEC-18
and the Bcl-XL–transfected clones cultured in suspension over-
night. Results represent the average plus the SEM of three inde-
pendent experiments.
Figure 6. Bcl-XL is not down-
regulated in suspension in the
IEC-18 variant AR 1.10 that
spontaneously acquired resis-
tance to anoikis. (A) Analysis
of apoptosis by cell death
ELISA in IEC-18 and AR
1.10 cells that were cultured
in suspension. Results repre-
sent the average of two inde-
pendent experiments plus the
SD. (B) Western blot analysis
of Bcl-XL in AR 1.10 cells
that were cultured in mono-
layer (mon) or in suspension
(susp) for the indicated time
periods. The membrane was
reprobed with an anti-CDK4
antibody as a loading control.
Figure 7. Enforced downregulation of Bcl-XL in the ras-trans-
formed cells with the antisense oligodeoxyribonucleotide results
in the inhibition of ras-induced resistance to anoikis. (A) West-
ern blot analysis of Bcl-XL in mock-transfected IEC-ras-3 cells,
IEC-ras-3 cells transfected with a control, or antisense Bcl-XL oli-
gonucleotides. The membrane was reprobed with anti-CDK 4 an-
tibody as a loading control. (B) Analysis of apoptosis by cell
death ELISA in mock-transfected IEC-ras-3 cells, IEC-ras-3 cells
transfected with a control, or antisense Bcl-XL oligonucleotides
that were cultured in monolayer or suspension overnight. Results
represent the average of duplicates plus the SD. Induction of
anoikis was calculated as the ratio of the apoptotic signal ob-
served in suspension versus the monolayer. This experiment was
performed three times with similar results.Rosen et al. Stabilization of Bcl-XL Expression Mediates ras-induced Inhibition of Anoikis453
on the induction of anoikis resistance stems from the
downregulation of Bak (Rosen et al., 1998).
ras-induced Stabilization of Bcl-XL Expression in 
Suspension Culture Does Not Require PI 3- and
MAP Kinases
ras is known to activate several signaling pathways through
effector molecules such as PI 3-kinase, Raf, Ral GDS,
MEKK, and AF-6 (Marshall, 1996; Katz and McCormick,
1997; Khosravi-Far et al., 1998). Two of these pathways,
the PI 3-kinase/PKB and Raf/MEK/ERK signaling cas-
cades, have been shown to be involved in the inhibition of
apoptosis in several cellular systems (Downward, 1998;
Scheid et al., 1999). Therefore, we decided to investigate
whether the ras-induced stabilization of Bcl-XL in IEC-18
cells requires activation of any of these two pathways. To
investigate the involvement of the PI 3-kinase/PKB path-
way, IEC-ras-3 cells were brought into suspension and
treated with the PI 3-kinase inhibitor LY 294002 at a con-
centration that we previously found to efficiently suppress
the activity of the enzyme in this particular cellular system
(Rosen et al., 1998). As expected, treatment with LY 294002
strongly suppressed the phosphorylation of PKB (Fig. 9
A) and, as previously reported (Rosen et al., 1998), caused
a significant increase in expression of Bak (Fig. 9 A). The
levels of Bcl-XL, on the other hand, were not affected (Fig.
8 A). This result is consistent with the fact that activated
PKB, a downstream mediator of the antiapoptotic effect
of PI 3-kinase, does not change the expression of Bcl-XL in
fibroblasts (Kennedy et al., 1997). Previously, we found
that ectopic expression of Bak in IEC-ras cells at levels
similar to, or even higher than, those in the parental IEC-18
cells causes only a partial reversal of ras-induced resis-
Figure 8. Enforced downregu-
lation of Bcl-XL in the ras-
transformed cells by trans-
fection with the full-length
antisense Bcl-XL cDNA results
in the inhibition of ras-induced
resistance to anoikis, anchor-
age-independent growth, and
tumorigenicity. (A) Western
blot analysis of Bcl-XL in
IEC-ras-3 cells, IEC-ras-3
clones transfected with an
antisense Bcl-XL expression
vector (as Bcl-X 65 and 66),
or vector alone (vector 75)
that were cultured in mono-
layer. The membrane was
probed with anti-PKB anti-
body as a loading control.
Cells were also probed for
Bak, Bax, and Bad. (B) West-
ern blot analysis of Bcl-XL in
IEC-18, IEC-ras-3 cells, and
IEC-ras-3 clones transfected
with an antisense Bcl-XL ex-
pression vector (as Bcl-X 65
and 66), or vector alone (vec-
tor 75) cultured in suspension
overnight. The membrane
was probed with anti-PKB
antibody as a loading control.
(C) Analysis of apoptosis by
cell death ELISA in IEC-
ras-3 and antisense Bcl-XL–
transfected clones cultured
in monolayer or suspension
overnight. Results represent
the average of two indepen-
dent experiments plus the
SD. Induction of anoikis was calculated as the ratio of the apoptotic signal observed in suspension versus monolayer, and the data are ex-
pressed as a percentage of the ratio measured for IEC-18 cells. (D) Growth of IEC-ras-3 and antisense Bcl-XL–transfected clones in an-
chorage-independent conditions. Cells were plated in soft agar in triplicates, and colonies were counted after 10 d. Results are expressed as
a percentage of the number of colonies obtained with IEC-ras-3 cells, and represent the average plus the SD of two independent experi-
ments. (E) Transfection of antisense Bcl-XL reduces the tumorigenicity of IEC-ras-3 cells. The indicated cell lines were injected subcutane-
ously into nude mice, and tumor volumes were measured at the indicated time points. The number of mice (n) used in each case is indi-
cated. Bars represent the SEM. This experiment was repeated twice with similar results.The Journal of Cell Biology, Volume 149, 2000 454
tance to anoikis (Rosen et al., 1998). Consistent with these
results, we found that the degree of death induced by LY
294002 in suspended IEC-ras cells constitutes only a frac-
tion of what is observed in untreated IEC-18 cells (data
not shown).
To investigate the potential involvement of the Raf/
MEK/ERK signaling IEC-ras-3 cells were placed in sus-
pension and treated with PD 98059, an inhibitor of MEK.
The treatment strongly suppressed phosphorylation of
ERK but did not change Bcl-XL expression (Fig. 9 B). Si-
multaneous treatment of suspended IEC-ras-3 cells with
LY 294002 and PD 98059 had no effect either (Fig. 9 C).
Overall, these results indicate that the resistance to anoikis
caused in intestinal epithelial cells by oncogenic ras is exe-
cuted by at least two major contributing pathways: one
that regulates Bcl-XL expression and, at least in our exper-
imental conditions, is independent of PI 3-kinase and
MEK, and another that downregulates Bak and requires
PI 3-kinase activity.
Discussion
We have shown here that in nonmalignant rat and human
intestinal epithelial cells, detachment from the ECM re-
sults in a significant downregulation of the antiapoptotic
protein Bcl-XL, and that activated ras completely abro-
gates such downregulation. The functional significance of
this finding was made evident by the demonstration that
ectopic expression of Bcl-XL in IEC-18 cells protected
them from anoikis, whereas enforced inhibition of Bcl-XL
expression in the ras-transformed cells promoted anoikis
and reduced tumorigenicity.
Activated ras is known to trigger multiple downstream
targets (Marshall, 1996; Katz and McCormick, 1997; Khos-
ravi-Far et al., 1998). We found that two of such targets, PI
3-kinase and MEK, are not involved in the effect of Ras on
Bcl-XL expression. The potential role of other ras effectors
in this phenomenon is the subject of our ongoing research.
About 50% of human colorectal tumors display overex-
pression of Bcl-XL when compared with the adjacent nor-
mal intestinal mucosa (Krajewska et al., 1996). Thus, based
on the findings reported here, it is tempting to speculate
that Bcl-XL overexpression may play a role in conferring
anoikis resistance to colorectal tumor cells, which are forced
to survive in the absence of contact with a properly formed
basement membrane during invasion and metastasis.
The overall conclusion that can be drawn from this
study as well as the previous one (Rosen et al., 1998) is
that the inhibition of anoikis in ras-transformed cells is, at
least in part, the result of the ability of this oncogene to
regulate the expression of two members of the Bcl-2 fam-
ily: Bcl-XL, an inhibitor of cell survival, and Bak, a well es-
tablished inducer of apoptosis. Interestingly, the regula-
tion of the expression of these molecules represents two
fundamentally different patterns of cell survival control in
the face of malignant transformation. Bak expression in
the nonmalignant IEC-18 cells is constitutively high, rela-
tively adhesion-independent, and a threshold level of ex-
pression of this protein is presumably required for the in-
duction of apoptosis upon cell detachment. Oncogenic
activation of ras leads to a dramatic downregulation of Bak
below the threshold levels that are required for apoptosis
of detached cells. In contrast, expression of Bcl-XL is highly
adhesion-dependent, and activated ras prevents Bcl-XL
downregulation, thereby providing the transformed cells
with an additional survival advantage under three-dimen-
sional growth conditions. Dissimilar modes of regulation
of both Bak and Bcl-XL are, understandably, associated
with differences in signaling events governing expression
of these molecules. While suppression of Bak in ras-trans-
formed IEC-18 cells can be reversed by the PI 3-kinase in-
hibitor LY294002, such treatment is ineffective in abrogat-
ing the stabilizing effect of activated ras on Bcl-XL.
Even though our data identify Bcl-XL and Bak as two
important mediators of the inhibitory effect of activated
ras on anoikis, the involvement of other components of
the apoptotic machinery in this effect cannot be excluded.
For example, in various cellular systems, the PI 3-kinase
signaling pathway is known to regulate the activity of Bad
(Datta et al., 1997; del Peso et al., 1997; Scheid and Duro-
nio, 1998), and Fas (Peli et al., 1999), two molecules with
well established roles in apoptosis. Among other candi-
date proteins that may act as mediators of the anoikis-
inhibitory effect of activated ras in intestinal epithelial
cells are members of the IAP family. In this respect, it is
important to note that the IAP survivin is deregulated in
several human tumors including colorectal carcinomas
(Ambrosini et al., 1997).
In summary, our study indicates that ras-induced resis-
tance to anoikis in intestinal epithelial cells is the result of
the ability of activated ras to alter the expression of at least
two components of the apoptotic machinery. This suggests
Figure 9. The stabilizing effect of activated ras on Bcl-XL expres-
sion is not suppressed by inhibition of PI 3-kinase, and Mek. (A)
Western blot analysis of Bcl-XL, phospho-PKB, PKB, and Bak in
IEC-ras-3 cells cultured in suspension overnight in the presence
(1) or absence (2) of 40 mM LY 294002 (LY). A similar volume
of DMSO (vehicle) was added to the untreated cells. The mem-
branes were reprobed with an anti-CDK 4 antibody as a loading
control. (B) Western blot analysis of Bcl-XL and phospho-MAP
kinase in IEC-ras-3 cells cultured in suspension overnight in the
presence (1) or absence (2) of 50 mM PD 98059 (PD). A similar
volume of DMSO (vehicle) was added to the untreated cells. The
membranes were reprobed with an anti-CDK 4 and MAP kinase
antibodies as loading controls. (C) Western blot analysis of Bcl-
XL in IEC-ras-3 cells cultured in suspension overnight in the
presence (1) or absence (2) of 40 mM LY 294002 and 50 mM PD
98059 (LY 1 PD). A similar volume of DMSO (vehicle) was
added to the untreated cells. The membrane was reprobed with
an anti-CDK 4 antibody as a loading control.Rosen et al. Stabilization of Bcl-XL Expression Mediates ras-induced Inhibition of Anoikis455
that therapeutic treatment aimed at the restoration of sen-
sitivity to anoikis of tumors carrying activated ras, while ex-
pected to have therapeutic effect, may require targeting the
ras oncogene directly instead of its downstream effector
molecules involved in the control of apoptosis.
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